CYP2C19Your two copies: *1/*2
Intermediate metabolizer
One copy works and one doesn't.
Handles several SSRIs, acid reducers such as omeprazole, and the blood thinner clopidogrel.
This result doesn't change the label.
Example report. Made from Leslie Knope's DNA data so you can see what yours will look like. Get your own report
Pain managementExample report
Carisoprodol
Soma
Use as directed
Your body breaks down carisoprodol slightly slower than normal. The standard dose should work as expected.
The genes behind this label
The guidelines read one gene for carisoprodol. Each card shows the two copies this person inherited and what they mean.
What the guidelines say
What each guideline says about your result.
CYP2C19Intermediate metabolizer
FDA drug label
Evidence: moderateSee the FDA table (U.S. Food and Drug Administration, opens in a new tab)
- In plain words
- Your body breaks down carisoprodol slightly slower than normal. The standard dose should work as expected.
- What it means
- No FDA guidance for this phenotype
- What the label suggests
- Initiate therapy with recommended starting dose.
Also an ingredient in
Carisoprodol is also in these combination products. The guidance above is for carisoprodol on its own. What this person's genes mean for a combination is less clear, so if someone takes one, it's worth talking over with a prescriber or pharmacist.
About carisoprodol
Carisoprodol (Soma) is a muscle relaxant for short-term relief of acute, painful muscle and joint conditions in adults.
- Used for
- Discomfort from acute, painful musculoskeletal conditions in adults, for up to two or three weeks
Others in pain management
Compare all 13 pain managementDon't change a dose on your own. Bring this report to your prescriber or pharmacist. They can weigh it with everything else they know about you.